Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pietro Arduini"'
Autor:
Filippo Valbusa, Stefano Bonapace, Davide Agnoletti, Luca Scala, Cristina Grillo, Pietro Arduini, Emanuela Turcato, Alessandro Mantovani, Giacomo Zoppini, Guido Arcaro, Christopher Byrne, Giovanni Targher
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0173398 (2017)
Nonalcoholic fatty liver disease (NAFLD) is an emerging risk factor for heart failure (HF). Although some progress has been made in improving survival among patients admitted for HF, the rates of hospital readmissions and the related costs continue t
Externí odkaz:
https://doaj.org/article/d23c3233db194b1e99efa824e9a1637e
Autor:
Davide Agnoletti, Giovanni Targher, Pietro Arduini, Aldo P. Maggioni, Giuliana Scaturro, Filippo Valbusa, Giacomo Zoppini, Alessandro Mantovani, Stefano Calabria, Stefano Bonapace, Luca Scala, Cristina Grillo, Emanuela Turcato, Guido Arcaro
Background: Nonalcoholic fatty liver disease (NAFLD) is an emerging risk factor for incident heart failure (HF). It is currently unknown whether NAFLD predicts all-cause mortality in patients admitted for acute HF. We aimed to assess whether NAFLD an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e234c4b6bd0be39feb29d1653cbe3c4
http://hdl.handle.net/11585/863916
http://hdl.handle.net/11585/863916
Autor:
Giovanni Targher, Cristina Grillo, Giacomo Zoppini, Pietro Arduini, Filippo Valbusa, Emanuela Turcato, Alessandro Mantovani, Guido Arcaro, Christopher D. Byrne, Davide Agnoletti, Stefano Bonapace, Luca Scala
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0173398 (2017)
PLoS ONE
PLoS ONE
Nonalcoholic fatty liver disease (NAFLD) is an emerging risk factor for heart failure (HF). Although some progress has been made in improving survival among patients admitted for HF, the rates of hospital readmissions and the related costs continue t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a40a3c92efe0dc57ac24d77eb2cc6f23
https://eprints.soton.ac.uk/406198/
https://eprints.soton.ac.uk/406198/
Autor:
Domenico Andreani, P. Pietravalle, Giancarlo Lombardi, Umberto Di Mario, Pietro Arduini, Claudio Tiberti
Publikováno v:
Diabetes Research and Clinical Practice. 2:317-324
The immunogenicity of biosynthetic human insulin (BHI) was studied in diabetic patients who had never received insulin treatment (Study A) and in diabetic patients who had already been treated with monocomponent insulin (Study B). The results of both